MANKIND - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.6
| Stock Code | MANKIND | Market Cap | 82,626 Cr. | Current Price | 2,001 ₹ | High / Low | 2,727 ₹ |
| Stock P/E | 46.8 | Book Value | 376 ₹ | Dividend Yield | 0.05 % | ROCE | 15.0 % |
| ROE | 13.9 % | Face Value | 1.00 ₹ | DMA 50 | 2,149 ₹ | DMA 200 | 2,282 ₹ |
| Chg in FII Hold | -1.49 % | Chg in DII Hold | 1.35 % | PAT Qtr | 513 Cr. | PAT Prev Qtr | 459 Cr. |
| RSI | 37.3 | MACD | -11.3 | Volume | 8,52,690 | Avg Vol 1Wk | 5,74,108 |
| Low price | 1,995 ₹ | High price | 2,727 ₹ | PEG Ratio | 5.56 | Debt to equity | 0.47 |
| 52w Index | 0.79 % | Qtr Profit Var | 24.5 % | EPS | 41.3 ₹ | Industry PE | 27.2 |
📊 Analysis: Mankind Pharma (MANKIND) trades at a high P/E of 46.8 compared to the industry average of 27.2, making it relatively expensive. ROE (13.9%) and ROCE (15.0%) are moderate, reflecting decent efficiency but not exceptional. The PEG ratio of 5.56 indicates valuations are stretched relative to growth. Dividend yield is negligible (0.05%), limiting income appeal. Quarterly PAT improved (513 Cr vs 459 Cr), showing earnings momentum. Technical indicators (RSI 37.3, MACD -11.3) suggest bearish momentum, with price below both 50 DMA (2,149 ₹) and 200 DMA (2,282 ₹). Debt-to-equity ratio of 0.47 indicates moderate leverage.
💡 Entry Price Zone: Ideal entry would be in the 1,950–2,050 ₹ range, closer to support levels, offering better risk-reward alignment.
📈 Exit Strategy: If already holding, consider partial exit near 2,600–2,700 ₹ resistance levels. For long-term investors, holding for 3–5 years is justified only if earnings growth accelerates to match valuations. Current fundamentals suggest cautious exposure.
✅ Positive
- Quarterly PAT growth of 24.5% highlights earnings momentum.
- EPS at 41.3 ₹ reflects solid earnings power.
- DII holdings increased (+1.35%), showing domestic institutional support.
⚠️ Limitation
- High P/E (46.8) compared to industry average (27.2).
- PEG ratio of 5.56 signals poor valuation-to-growth alignment.
- Dividend yield is negligible (0.05%), limiting income appeal.
📉 Company Negative News
- FII holdings decreased (-1.49%), showing reduced foreign investor confidence.
- Stock trading below both 50 DMA and 200 DMA indicates bearish trend.
📈 Company Positive News
- Quarterly PAT improved (513 Cr vs 459 Cr previous quarter).
- EPS growth supports valuation stability.
🏭 Industry
- Pharma sector trades at average PE of 27.2, making Mankind relatively expensive.
- Industry growth supported by demand for generics, specialty drugs, and healthcare expansion.
🔎 Conclusion
Mankind Pharma is fundamentally strong but trades at expensive valuations compared to peers. Long-term investors should consider entry around 1,950–2,050 ₹ for optimal risk-reward. Existing holders may maintain positions for 3–5 years, with partial exits near resistance levels. The stock is a moderate candidate for long-term investment, contingent on earnings growth catching up with valuations.